Document:

License and Supply Agreement

 Exhibit 10.1 

CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 

LICENSE AND SUPPLY AGREEMENT 

This License and Supply Agreement (the “Agreement”) is made as of May 26, 2010 (the “Effective Date”) by and
between Arius Pharmaceuticals, Inc. (“BDSI”), and BioDelivery Sciences International, Inc. (“Parent”), with an office at 801 Corporate Center Drive, Raleigh, North Carolina 27607 USA, and KUNWHA Pharmaceutical Co., Ltd., a
corporation organized under the laws of the Republic of Korea, with an office at Kunwha Bldg, 94, Karak-Dong, Songpa-Gu, Seoul, 138-804, Korea, (“Kunwha”). BDSI and Kunwha are sometimes referred to collectively herein as the
“Parties” or singly as a “Party.” 
 R E C I T A L S 

WHEREAS, BDSI wishes to grant to Kunwha, and Kunwha wishes to obtain from BDSI, an exclusive license to develop, manufacture (or
have manufactured), market, advertise, promote, distribute, offer for sale, sell, and import BDSI’s BEMA fentanyl product in the Republic of Korea on the terms and subject to the conditions set forth herein. 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants and agreements contained herein, the Parties
hereto, intending to be legally bound, do hereby agree as follows: 
 1. DEFINITIONS 

In addition to the capitalized terms defined elsewhere in this Agreement, the following terms used in this Agreement shall have the
meaning set forth below: 
 1.1 “ADE” means any Adverse Event associated with the Licensed Product or the
Demonstration Samples (including Adverse Drug Reactions). 
 1.2 “Adverse Event” or “AE” means
any untoward medical occurrence in a patient or clinical investigation subject administered Products and which does not necessarily have to have a causal relationship with such treatment. 

1.3 “Adverse Reaction” or “Adverse Drug Reaction” or “ADR” means a response to any
Product which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease or for modification of physiological function. 

1.4 “Affiliate” means an individual, trust, business trust, joint venture, partnership, corporation, association or any
other entity which owns, is owned by or is under common ownership with, a Party. For the purposes of this definition, the term “owns” (including, with correlative meanings, the terms “owned by” and “under common ownership
with”) as used with respect to any Party, shall mean the possession (directly or indirectly) of more than 50% of the outstanding voting securities of a corporation or comparable equity interest in any other type of entity. 

 

 1 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 1.5 “API” means active pharmaceutical ingredient. 

1.6 “Applicable Laws” means all applicable laws, rules, regulations and guidelines that may apply to the development,
marketing, manufacturing or sale of the Licensed Product or the performance of either Party’s obligations under this Agreement, including but not limited to all laws, regulations and guidelines governing the import, export, development,
marketing, distribution and sale of the Licensed Product in the Territory, to the extent relevant, all Good Manufacturing Practices or Good Clinical Practices standards or guidelines promulgated by the FDA, other Competent Authorities, or the
International Conference on Harmonization, and all laws, rules, regulations, and guidelines applicable to the manufacture, use, shipment, handling, sale, marketing, and distribution of fentanyl as a Schedule II controlled substance under the United
States’ Controlled Substances Act and any similar foreign laws, rules, and regulations, and trade association guidelines (including but not limited to, with respect to all of the foregoing, those which apply to the handling of narcotics), where
applicable. 
 1.7 “BEMA” means the proprietary bioerodible, mucoadhesive multi-layer polymer film technology
Controlled by BDSI. 
 1.8 “Bundled Product” means any Licensed Product when (i) sold together with
any other products and/or services within the Territory at a unit price, whether packaged together or separately with another pharmaceutical product or other device, equipment, instrumentation, or other components (other than solely containers or
packaging exclusively for such Licensed Product), (ii) used as a “loss leader”, (iii) a discount, rebate, or similar financial incentive is offered on the Licensed Product as consideration or incentive for a Third Party to buy
other products or services from Kunwha or any Affiliate thereof, or (iv) such Licensed Product is otherwise bundled with sales of any other products or services in any discounting program.  

1.9 “Calendar Quarter” means the respective periods of three consecutive calendar months ending on
March 31, June 30, September 30 and December 31, provided the initial Calendar Quarter under this Agreement shall begin on the Effective Date and end on the first March 31, June 30, September 30
or December 31 following the Effective Date. 
  

 2 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 1.10 “Calendar Year” means each twelve consecutive month period
beginning January 1 and ending December 31, provided that the initial Calendar Year under this Agreement shall begin on the Effective Date and end December 31, 2010. 

1.11 “Commercially Reasonable Efforts” means, except as otherwise explicitly set forth in this Agreement, efforts
consistent with the reasonable exercise of prudent scientific and business judgment and generally accepted practices in the pharmaceutical industry, as applied to similar products having comparable market potential. “Comparable market
potential” shall be ***. Commercially Reasonable Efforts requires that a Party, ***. 
 1.12
“Commercial Sale” means the sale for use, consumption or resale of a Licensed Product in the Territory by Kunwha or its Affiliates. 

1.13 “Competent Authorities” means collectively the governmental entities in the Territory responsible for the
regulation of medicinal products intended for human use, including but not limited to the Korea Food & Drug Administration (“KFDA”). 

1.14 “Competing Product” means a pharmaceutical product that: (a) is labeled for the indication of breakthrough
pain and (b) incorporates fentanyl as an API. 
 1.15 “Confidential Information” means any confidential or
proprietary information of a Party, whether in oral, written, graphic or electronic form. Any of the following information, which the receiving Party can prove by competent evidence, shall not be Confidential Information: 

(a) information that is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party,
generally known or available; 
 (b) information that is known by the receiving Party at the time of receiving
such information, as evidenced by its written records maintained in the ordinary course of business; 
 (c)
information that is hereafter furnished to the receiving Party by a Third Party, as a matter of right and without restriction on disclosure; 
  

 3 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 (d) information that is independently developed by the receiving Party,
as evidenced by its written records maintained in the ordinary course of business, without knowledge of, and without the aid, application or use of, the disclosing Party’s Confidential Information; or 

(e) information that is the subject of a written permission to disclose provided by the disclosing Party. 

1.16 “Control” means the possession of the ability to grant a license or sublicense as provided for herein without
violating the terms of any agreement or other arrangement with any Third Party existing on the Effective Date or, with respect to any intellectual property rights acquired from a Third Party following the Effective Date, any agreements in effect at
the time such rights are acquired. 
 1.17 “Demonstration Samples” means Units, lacking fentanyl, used to
demonstrate the manner in which the Licensed Product is prepared and used, and labeled “demonstration samples, for demonstration purposes only.” 

1.18 “Development Documentation” means all documentation, including notes, summaries and analyses related thereto,
developed in connection with all research, development, or clinical trials performed by or on behalf of Kunwha in the Territory under this Agreement (including but not limited to any research and development or Phase IV studies performed following
Governmental Approval). 
 1.19 “Field” means the treatment of breakthrough cancer pain in humans (the
“Initial Indication”) and, following Governmental Approval in the Territory of the Licensed Product for the Initial Indication, any additional human therapeutic indications for which Governmental Approval is obtained. 

1.20 “First Commercial Sale” means the first Commercial Sale of the Licensed Product in the Territory. 

1.21 “Forecast” means the written forecast describing Kunwha’s anticipated requirements with respect to Products
for a given time period, including the proposed delivery schedule with respect to such Products. 
  

 4 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 1.22 “Fully-Burdened Manufacturing Costs” means BDSI’s total
direct and indirect costs of supplying a particular Product to Kunwha hereunder, which shall include the costs of all raw materials, services, and labor used or consumed in the manufacture, distribution, and supply of Product hereunder, packaging
costs and expenses, costs for lot failures, batch failures, or other quality control or production failures, shipping, handling, storage, and delivery costs related to the Product, quality assurance and quality control related expenses, any costs
incurred under contracts with Third Parties concerning the development and/or supply of Product to be supplied to Kunwha hereunder, administrative and regulatory expenses related to the procurement, manufacture, and supply of Product, and all other
overhead amounts allocable to procurement, manufacture, and supply of Product. 
 1.23 “Governmental Approval”
means all permits, licenses and authorizations, including but not limited to, import permits and Marketing Authorizations required by any Competent Authority as a prerequisite to the manufacturing, marketing or selling of the Licensed Product for
human therapeutic use in the Territory. 
 1.24 “Improvements” means any and all developments, inventions or
discoveries relating to BEMA or the Licensed Technology that are developed or acquired by, or otherwise come under the Control of, a Party or any Affiliate thereof and shall include, but not be limited to, such developments intended to enhance the
safety and/or efficacy of the Licensed Product. 
 1.25 “KNDA” means a new drug application, all amendments and
supplements thereto, and all additional documentation required to be filed in the Territory for approval to commence commercial sale of the Licensed Product in the Republic of Korea. 

1.26 “Know-How” means all know-how, trade secrets, inventions, data, processes, techniques, procedures, compositions,
devices, methods, formulas, protocols and information, whether or not patentable, which are not generally publicly known, including, without limitation, all chemical, biochemical, toxicological, and scientific research information, whether in
written, graphic or video form or any other form or format. 
 1.27 “Licensed Know-How” means all Know-How
related to the Licensed Product which is under the Control of BDSI as of the Effective Date. 
 1.28 “Licensed
Patent Rights” means all Patent Rights in the Territory claiming the Licensed Product, or that are necessary to develop, manufacture and commercialize the Licensed Product in the Territory (including all such patents claiming Improvements
or the composition of matter, formulation or method of manufacture or use of the Licensed Products), to the extent under the Control of BDSI. 
  

 5 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 1.29 “Licensed Product” means the 200mcg, 400mcg, 600mcg, 800mcg, and
1200mcg dosage strengths of that BEMA-based product which (i) contains fentanyl as it sole API, (ii) is currently the subject of MAA DCP DE-H-1660-001-006-DC, and (iii) is supplied to Kunwha by (or on behalf of) BDSI. 

1.30 “Licensed Technology” means the Licensed Patent Rights and the Licensed Know-How. 

1.31 “Marketing Authorization” means all necessary and appropriate regulatory approvals, including but not limited to
variations thereto and, if applicable or reasonably advisable with respect to a particular jurisdiction, Pricing and Reimbursement Approvals to put the Licensed Product on the market for sale for human therapeutic use in the Territory. 

1.32 “Net Sales” means the gross amounts invoiced or received by Kunwha or its Affiliates for their sales of Licensed
Product to Third Parties in bona fide arm’s length transactions, less the following deductions, to the extent reasonable and customary: ***. 

1.32.1 Licensed Product shall be considered sold when billed out or invoiced or, if sooner, when payments are received. Components of Net
Sales shall be determined in the ordinary course of business in accordance with historical practice and using the accrual method of accounting in accordance with IFRS. 

1.32.2 In the event Kunwha or any Affiliate thereof transfers Licensed Product to a Third Party in a bona fide arm’s length
transaction for consideration, in whole or in part, other than cash or to a Third Party in other than a bona fide arm’s length transaction, the Net Sales price for such Licensed Product ***. The Net Sales of a Bundled Product shall be
calculated ***. 
 1.32.3 Notwithstanding anything to the contrary, in the event that Kunwha or its Affiliates sells
Licensed Product to a Third Party at a discount that is greater than the discount generally given to such Third Party for their other products sold to such Third Party (including establishing a list price at a lower than normal level), then Net
Sales to such Third Party shall be deemed to ***. 
 1.33 “NHI” means the National Health Insurance program of
the Republic of Korea. 
  

 6 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 1.34 “Order” means a written purchase order for Products, which order
shall include a delivery schedule specifying the requested delivery date and quantity for each Product ordered. 
 1.35
“Patent Rights” means all rights under patents and patent applications, and any and all patents issuing therefrom (including utility, model and design patents and certificates of invention), together with any and all substitutions,
extensions (including supplemental protection certificates), registrations, confirmations, reissues, divisionals, continuations, continuations-in-part, re-examinations, renewals and domestic and foreign counterparts of the foregoing. 

1.36 “Placebo” means a bioerodible, mucoadhesive polymer film product that does not contain fentanyl, but is otherwise
indistinguishable from, and is intended to be administered in the same way as, the Licensed Product for purposes of preclinical testing and clinical studies. 

1.37 “Pricing and Reimbursement Approvals” means any pricing and reimbursement approvals which must be obtained before a
Licensed Product can legally be placed on the market in the Territory for sale as a human therapeutic. 
 1.38
“Product” means the Licensed Product, Placebos, and Demonstration Samples. 
 1.39 “Product
Development” means all actions reasonably necessary in connection with seeking and obtaining Governmental Approval of the Licensed Product in the Territory, including, if and as necessary, the performance of clinical trials of the Licensed
Product in the Territory in accordance with this Agreement. 
 1.40 “Product Price” means BDSI’s *** costs
of supplying a particular Unit to Kunwha ***.  
 1.41 “Product Recall” means any recall or market
withdrawal of any Product from or in the Territory. 
 1.42 “Product Specifications” means the manufacturing
and product specifications, which comply with the applicable regulatory requirements of FDA or EMEA, for the applicable Product set forth on Annex I, attached hereto, as they may be amended from time to time in accordance with this Agreement.

  

 7 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 1.43 “Results” means the results from all research, development, and
clinical trials performed by or on behalf of Kunwha or its Affiliates, including but not limited to that reported on Development Documentation. 

1.44 “Royalty Fee” means an amount *** of the Net Sales *** of the Net Sales price per Unit of Licensed Product ***.

 1.45 “Serious Adverse Event” or “SAE” means an Adverse Event that at any dose
(i) results in death, (ii) is life-threatening, (iii) requires inpatient hospitalization or prolongation of existing hospitalization, (iv) results in persistent or significant disability/incapacity, or (v) is a congenital
anomaly/birth defect. The term “life-threatening” in this definition refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it
had been more severe. Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or require intervention to prevent one of the other outcomes listed above should also be
included in this definition to the extent reasonable medical and scientific judgement indicates that expedited reporting is appropriate under Applicable Laws. 

1.46 “Serious Adverse Reaction” or “SAR” means an Adverse Reaction that at any dose (i) results in
death, (ii) is life-threatening, (iii) requires inpatient hospitalization or prolongation of existing hospitalization, (iv) results in persistent or significant disability/incapacity, or (v) is a congenital anomaly/birth defect.
The term “life-threatening” in this definition refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it had been more severe.
Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or require intervention to prevent one of the other outcomes listed above should also be included in this
definition to the extent reasonable medical and scientific judgement indicates that expedited reporting is appropriate under Applicable Laws. 

1.47 “Term” means the period from the Effective Date until the date of expiration of PCT/US07/16634
(WO 2008/011194) filed in South Korea as 10-2009-7003532, or July 23, 2027, whichever is later.  
 1.48
“Territory” means the Republic of Korea. 
  

 8 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 1.49 “Third Party” means any entity other than: (a) BDSI,
(b) Kunwha, or (c) an Affiliate of BDSI or Kunwha. 
 1.50 “Unit” means a single saleable unit of
Licensed Product. 
 1.51 “Valid Claim” means a claim of any pending patent application or issued and unexpired
Patent Right that has not been disclaimed, revoked, held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that
has not been admitted to be invalid or unenforceable through re-examination, re-issue, disclaimer or otherwise, or lost in an interference proceeding. 

2. CLINICAL, REGULATORY AND GOVERNMENTAL APPROVAL. 

2.1 Kunwha shall use Commercially Reasonable Efforts to pursue Product Development for the Licensed Product in the Field in the
Territory. Kunwha will carry out development work substantially pursuant to a detailed development plan, which plan must be approved in advance and in writing by BDSI (such plan, as approved, the “Development Program”). Kunwha shall not
perform, nor enable any Affiliate or Third Party to perform, and research and development concerning the Licensed Product except as provided in the Development Program. Notwithstanding anything to the contrary, Kunwha shall be entitled to carry out
the Development Program through the use of Third Party contractors, provided that Kunwha shall be responsible and liable for such Third Party’s performance of and compliance with Kunwha’s obligations hereunder. The Development Program may
be amended by Kunwha from time to time, subject to the advance review and written approval by BDSI in writing of such amendments. Kunwha shall provide BDSI with detailed written reports regarding the status, progress, and outcome, as well as major
findings and major decision points, of Product Development at least once per Calendar Quarter during the Term, which reports shall be delivered no later than *** following the end of the applicable quarter. 

2.2 Kunwha shall maintain books and records in connection with the Development Program in accordance with Applicable Laws and otherwise
in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, including to obtain Governmental Approvals, and shall properly reflect all material work done and results achieved by or on behalf of Kunwha in the
performance of the Development Program in such books and records. BDSI and its designees shall have the right to access, audit, and inspect the materials in such books and records and any facilities engaged in Product Development by or on behalf of
Kunwha, and Kunwha shall without undue delay provide copies of such books and records, and access to any such facilities, to BDSI and/or its designees upon their reasonable request. BDSI or its designees may audit and inspect such books, records,
and facilities at any time for cause upon reasonable notice to Kunwha. 
  

 9 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 2.3 The Parties acknowledge that the Licensed Product has been reviewed and approved for
sale and use as a human therapeutic product in the United States. Kunwha shall use Commercially Reasonable Efforts to prepare and file in the Territory all required application(s) for Governmental Approval of the Licensed Product, including all
necessary regulatory documents. 
 2.4 Subject to the terms of the License Agreement, Kunwha shall be responsible for the
compilation and submission of the regulatory filings in respect of the Licensed Product in the Territory, the holder of any Governmental Approvals granted for the Product, and responsible for interaction with Competent Authorities in the Territory,
provided that (i) no filing, submission, or correspondence shall be made to any Competent Authority or other governmental authority or agency concerning the Licensed Product in the Territory without providing BDSI a reasonable opportunity to
review such filing, submission, or correspondence and obtaining BDSI’s prior written consent with respect to the content thereof and (ii) Kunwha shall provide BDSI prompt advance written notice of, and a reasonable opportunity to attend
and participate in, any meetings (in person, telephonic or otherwise) with any Competent Authorities or other governmental authorities or agencies concerning Licensed Products in the Territory. Kunwha shall reasonably advise BDSI in detail regarding
the status of or developments with respect to the regulatory filings and Governmental Approvals but not less than at the end of every Calendar Quarter in accordance with terms of this Agreement. In regard to this section 2.4, Kunwha will provide
BDSI with a summary containing the material details of interactions with any Competent Authorities in English. Thereafter, should BDSI require additional information regarding the interaction with the Competent Authorities, Kunwha will provide BDSI
full translations, in English, of any documents (including any minutes, notes or other documents) BDSI might request at BDSI’s cost. 

2.5 BDSI shall, upon Kunwha’s reasonable request, promptly provide to Kunwha all information, which is in BDSI’s possession and
that BDSI has the right to provide to Kunwha, regarding BDSI’s (or its Third Party contractors’) manufacturing facilities, methods and process controls for the manufacture of the Product, and will reasonably assist Kunwha in compilation of
information for the chemistry, manufacturing and control documentation which Kunwha reasonably determines in good faith is needed for completion of the regulatory filings. In the event that BDSI reasonably determines that any such information
constitutes proprietary, confidential, or trade secret information belonging to BDSI or its Third Party contractor(s), the parties will cooperate to take appropriate steps to preserve the confidential, proprietary and/or trade secret status of such
information. 
  

 10 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 2.6 Kunwha shall, as promptly as reasonably possible, provide to BDSI reports and other
written communications received by Kunwha from any Competent Authority concerning the Licensed Product or any activities of Kunwha or its Affiliates related thereto. On or after the date of First Commercial Sale of the Licensed Product, each Party
shall provide the other Party with a status update with regard to any audit or inspection conducted by any Competent Authority which relates directly to the Licensed Product. 

2.7 Subject to the terms of this Agreement, Kunwha shall be responsible for obtaining and maintaining all Governmental Approvals
necessary for Kunwha to contract BDSI to manufacture and package the Licensed Product into final packaging. Subject to the terms of this Agreement, Kunwha shall be responsible for obtaining and maintaining all applicable Governmental Approvals for
the commercial marketing, sale, and distribution of the Licensed Product in the Territory. 
 2.8 Kunwha shall be solely
responsible for the payment of all costs incurred by it with respect to the Licensed Product in the Territory, including any and all costs incurred with respect to the development of the Licensed Product as a condition to the granting of
Governmental Approval of the Licensed Product for all indications. 
 2.9 Subject to Sections 3.2 and 9.5 Kunwha shall own all
rights in and to any Governmental Approval and related documentation, including all notes, summaries and analyses related thereto, developed in connection with such Governmental Approval. BDSI shall provide Kunwha with copies of and access to
Licensed Know-How in BDSI’s possession, including but not limited to information reasonably sufficient for allowing Kunwha to establish and undertake Commercially Reasonable Efforts to maintain and comply with Governmental Approvals in the
Territory. 
 2.10 Upon request, Kunwha shall provide BDSI with copies of and access to information in Kunwha’s possession,
including but not limited to information reasonably sufficient for allowing BDSI to establish, exercise and enforce its rights under this Agreement (including its right of reference with respect to Development Documentation and Results and the right
to audit and inspect the books and records, in any media or form, of Kunwha according to Sections 12.1 and 13.12), and BDSI shall neither disclose nor distribute to any Third Party the Clinical Documentation and Results provided by Kunwha without
Kunwha’s prior written consent, such consent not to be unreasonably withheld, except (A) to the extent necessary to comply with its obligations under this Agreement or exercise or enforce its rights under this Agreement (B) to any
regulatory or governmental authorities, or to any Third Party, as required by applicable law, rule, regulation, or judicial order, and, (C) only under conditions of written confidentiality, to any licensor, licensee or sublicensee of BDSI or
their Affiliates and only in regards to a BEMA based product. BDSI’s obligation to obtain prior written consent before disclosing or distributing the Clinical Documentation and Results will survive the expiration of this Agreement. The
foregoing shall not be interpreted to grant ownership to Kunwha in any results or research and development conducted by or on behalf of BDSI outside the Territory, regardless of whether or not such results are referred to in any regulatory
submissions of Kunwha. 
  

 11 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 2.11 The Parties shall keep each other promptly and fully informed about any material
adverse events, side effects, injury, toxicity or sensitivity reaction associated with the Product of which such Party becomes aware, whether or not any such effect is attributable to the Product. Kunwha shall be responsible for reporting relevant
side effects to the appropriate regulatory authorities in accordance with the terms of this Agreement and all Applicable Laws. Each shall promptly inform the other by telephone and in writing in the event any circumstances occur which may
precipitate a possible or actual recall of any Product. 
 3. LICENSES 

3.1 Subject to the terms and conditions of this Agreement, BDSI, along with Parent hereby grant to Kunwha during the Term an exclusive,
royalty-bearing license, without rights of sublicense, in the Field under the Licensed Technology to market, advertise, promote, distribute for commercial sale, offer for sale, sell, and import for commercial sale the Licensed Product in the
Territory and BDSI hereby grants to Kunwha during the Term a non-exclusive license under the Licensed Technology to develop in the Territory the Licensed Product for additional human therapeutic indications following Governmental Approval of such
Licensed Product in the Territory for the Initial Indication. 
 3.2 Subject to the rights of Kunwha under this Agreement,
Kunwha hereby grants to BDSI an non-exclusive worldwide royalty-free license and right of reference, with rights of sublicense, under the Governmental Approvals, Development Documentation, and Results for (i) the development, manufacturing and
commercialization of any BEMA-based products, (ii) the research and development of the Licensed Product, and (iii) the commercialization of the Licensed Product outside the Territory. 

 

 12 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 3.3 During the Term of this Agreement, BDSI and its Affiliates shall not sell, market,
distribute, or offer for sale the Licensed Product in the Territory, nor grant any right or license to any Third Party with respect to the Licensed Product in the Territory that conflicts with the rights granted to Kunwha under this Agreement.
Notwithstanding anything to the contrary, nothing in this Agreement shall limit BDSI’s or its Affiliates’ or BDSI’s or its Affiliates’ sublicensees’ right to research or develop commercialize, market, sell, promote,
distribute, import or manufacture BEMA products, other than the Licensed Product, in the Territory, or to manufacture, use, sell, offer for sale, promote, import, or distribute the Licensed Product and BEMA products for use outside the Territory or
enter into an agreement with any Third Party enabling such Third Party to engage in such activities with respect to the Licensed Product. 

3.4 Kunwha acknowledges that it shall have no right, title or interest in or to the Licensed Technology or Licensed Product except to the
extent set forth in this Agreement, and BDSI reserves all rights to make, have made, use, sell, offer for sale, and import the Licensed Technology and Licensed Product except as otherwise expressly granted to Kunwha pursuant to this Agreement.
Nothing in this Agreement shall be construed to grant Kunwha any rights or license to any intellectual property of BDSI other than as expressly set forth herein. 

3.5 All Affiliates of Kunwha shall be subject to the terms of this Agreement. Kunwha shall be fully responsible and liable for the acts
and omissions of its Affiliates in the course of exercising any rights granted under this Agreement as if such acts or omissions had been those of Kunwha, including but not limited to any breach of the provisions of this Agreement, and Kunwha shall
ensure that all of Kunwha’s Affiliates shall comply with the terms of this Agreement. 
 3A. PATENTS AND INTELLECTUAL
PROPERTY 
 3A.1 BDSI shall, upon Kunwha’s written request, provide all the documents materially relevant to patent
application and prosecution of PCT/US07/16634 (WO2008/011194) filed in the Republic of Korea as patent application 10-2009-7003532 including, but not limited to any communication or correspondences with patent examiners in the Territory, amendments
or remarks/arguments submitted to KIPO, and a notice of allowance issued by KIPO. In case a notice of allowance is issued by KIPO, BDSI shall notify Kunwha of its occurrence and BDSI shall cooperate with Kunwha, as reasonably requested thereby at
Kunwha’s expense, to record in KIPO the exclusive license to the patent derived from the patent application 10-2009-7003532 under this Agreement. Kunwha shall bear the exclusive license recordation cost. 

 

 13 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 3A.2 Kunwha shall make available to BDSI or its authorized attorneys, agents or
representatives, its employees and, to the extent reasonably practicable, its consultants or agents as are necessary or appropriate to enable BDSI to file, prosecute and maintain patent applications for the Licensed Patent Rights in the Territory,
and with respect to Improvements, anywhere in the world, for a reasonable period of time sufficient for BDSI to obtain the assistance it needs from such personnel. Kunwha and BDSI share all reasonable, documented costs and expenses incurred in
making its attorneys, agents, representatives or consultants available pursuant to the foregoing. 
 3A.3 During the Term, each
Party shall give prompt notice to the other Party of any Third Party act which may infringe Kunwha’s rights under the Licensed Patent Rights in the Territory and shall cooperate with the other Party to terminate such infringement. If legal
proceedings become necessary, BDSI shall have the sole right, to bring and control such action or proceeding concerning the potential or actual infringement of Kunwha’s rights under this Agreement, and, unless otherwise agreed upon in writing
by the Parties, BDSI shall solely bear the cost with respect thereto. Kunwha shall provide, at BDSI’s expense (unless otherwise agreed to by the Parties in writing), such assistance and cooperation to BDSI as may be necessary to successfully
prosecute any action against such Third Party. Any damages, monetary awards, or other amounts recovered or received in settlement by BDSI with respect to any infringement of the rights to Licensed Patent Rights granted under this Agreement shall be
applied proportionately first to defray the unreimbursed costs and expenses (including reasonable attorneys’ fees) incurred by Kunwha and BDSI in the action. If any balance remains, BDSI and Kunwha shall in good faith negotiate how the
remaining balance will be distributed based on the Parties’ respective interests in the Licensed Patent Rights. 
 3A.4 In
the event a Third Party commences a judicial or administrative proceeding against a Party and such proceeding, other than a proceeding concerning the filing, prosecution, or maintenance of the Licensed Patent Rights, pertains to the use, sale,
marketing, or import of the Licensed Product in the Territory (the “Third Party Claim”), or threatens to commence such a Third Party Claim, the Party against whom such proceeding is threatened or commenced shall give prompt notice to the
other Party. Kunwha shall, using counsel reasonably acceptable to BDSI, at Kunwha’s own cost and expense, defend any and all such Third Party Claims or proceedings made with respect to the activities of Kunwha, its Affiliates, and its agents,
and BDSI shall, at Kunwha’s cost and expense, provide such assistance and cooperation to Kunwha as may be necessary to successfully defend any such Third Party Claims. The above notwithstanding, Kunwha may only settle any such claim with
BDSI’s prior written consent, such consent not to be unreasonably withheld. The above notwithstanding, if Kunwha does not defend a Third Party Claim in a reasonably timely manner (as determined by BDSI in its reasonable discretion), and such
Third Party Claim involves a material adverse risk to either Party, the Licensed Patent Rights, any other Patent Rights owned, licensed, or controlled by BDSI, the ability to develop or commercialize the Licensed Product in the Territory, or Net
Sales, this Agreement may be terminated or rendered nonexclusive by BDSI upon written notice to Kunwha, and, in any event and independent of any termination or rendering nonexclusive of this Agreement by BDSI pursuant to the foregoing, BDSI shall
have the right, but not the obligation, to control the defense of any claims made against BDSI or any Affiliate thereof at BDSI’s cost and expense using counsel of its own choice. Any damages, monetary awards, or other amounts recovered or
received in settlement by Kunwha with respect to the defense of any such action described in this Section 3A.4 shall be applied proportionately first to defray the unreimbursed costs and expenses (including reasonable attorneys’ fees)
incurred by Kunwha and BDSI in the action. If any balance remains, BDSI and Kunwha shall in good faith negotiate how the remaining balance will be distributed based on the Parties’ respective interests in the Licensed Patent Rights. 

 

 14 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 3A.5 Notwithstanding anything to the contrary, Kunwha shall not, and shall ensure that
none of its Affiliates, contractors, or other agents does not, take any action or make any statement that, directly or indirectly, adversely affects, or would reasonably be expected to adversely affect, any of the Licensed Patent Rights or Licensed
Know-How, or BDSI’s or any BDSI Affiliate’s or sublicensees’ rights or ability to make, use, sell, offer for sale, or import Licensed Product or other BEMA-based product. 

3A.6 BDSI shall own all right, title and interest in and to any Improvements made by or on behalf of BDSI (or any Affiliate thereof).
Kunwha shall own all right, title and interest in and to any improvements made by or on behalf of Kunwha (or any Affiliate thereof). Improvements hereunder made jointly by both Parties shall be owned jointly by the Parties. 

3A.7 The Parties agree that all information concerning Improvements made by BDSI shall be deemed the Confidential Information of BDSI and
that BDSI shall be the disclosing party, and Kunwha the receiving party and vice versa. 
  

 15 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 4. FINANCIAL TERMS 

ROYALTY, MILESTONE AND PURCHASE PRICE PAYMENTS 

4.1 In partial consideration for the licenses granted hereunder, Kunwha shall pay to BDSI an initial one-time non-refundable,
non-creditable license fee of US$300,000, by wire transfer of immediately available funds to an account to be designated by BDSI. Kunwha shall pay such license fee as soon as reasonably possible following execution of this Agreement, but in any
event within ten (10) business days of the Effective Date. 
 4.2 Kunwha shall pay to BDSI, as additional license fees, the
following nonrefundable, noncreditable milestone payments upon the occurrence of each of the specified milestone events: 

4.2.1 US$300,000 ***; 

4.2.2 US$300,000 upon ***; 

4.2.3 US$175,000 ***; and 

4.2.4 US$200,000 ***. 

For the avoidance of doubt, each milestone payment referred to in this Section 4.2 shall be paid only once by Kunwha. Kunwha shall
provide BDSI with written notice of each milestone above, and shall pay BDSI the designated amount for the applicable milestone, within ten (10) business days of achievement of the relevant milestone. 

4.3 Kunwha shall, in addition to the purchase price for the supply of Licensed Product described in Section 4.4 below, pay BDSI the
Royalty Fee for all Licensed Products sold in the Territory. 
 4.4 Kunwha shall purchase from BDSI all Licensed Product
intended for Commercial Sale in the Territory at a price equal to ***. 
 4.5 Kunwha shall purchase from BDSI all Products ***
at a price equal to ***. 
 4.6 Kunwha shall, in its sole discretion, have the sole and exclusive right to
determine all terms and conditions of sale of the Product to its customers, subject to the constraints and requirements of any applicable Governmental Approvals and the terms of this Agreement. 

 

 16 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 4.7 Kunwha, on behalf of itself and its Affiliates, shall, beginning with the Calendar
Quarter during which the first sale of the Licensed Product occurs in the Territory, furnish to BDSI a quarterly written report (each, a “Royalty Statement”) showing in reasonably specific detail (i) Kunwha’s, and its Affiliates
inventory on hand of each Stock Keeping Unit (“SKU”) of Units, sales in Units per SKU during such Calendar Quarter, and Net Sales during such Calendar Quarter; (ii) amounts payable under this Agreement with respect to such Calendar
Quarter based upon Net Sales (which shall include a detailed accounting of all amounts and calculations required to determine Net Sales); (iii) exchange rate(s) used in calculating payments due under this Agreement, (iv) withholding taxes,
if any, required by law to be deducted with respect to any payments due BDSI under this Agreement; and (v) any other information requested by BDSI. Such report shall be provided within *** following the close of each Calendar Quarter

 4.8 All payments due BDSI under Section 4.3 with respect to Licensed Products sold during a particular Calendar Quarter
shall be paid no later than *** following the close of such Calendar Quarter. All payments under this Agreement shall be payable in United States Dollars and made by wire transfer to a bank account designated by the Party owed payment, unless
otherwise specified in writing by such Party. 
 4.9 With respect to any payment made under this Agreement that are calculated
on the basis of amounts invoiced or received by Kunwha in Korean won or any other currency other than United States Dollars, such conversion shall be made at the rate of exchange reported in The Wall Street Journal on the last business day of
the (i) Royalty Quarter during which Licensed Products are sold, for any amounts calculated on the basis of Net Sales of Licensed Products, or (ii) the Calendar Quarter preceding such payment, for all other payments 

4.10 In the event that any payment due hereunder is not made when due, each such payment shall accrue interest from the date due at an
annual rate equal to the prime rate of interest (as last published in the Wall Street Journal) plus *** or, if less, the maximum legally permissible interest rate, calculated on the number of days such payments are paid after the date such
payments are due. The payment of such interest shall not limit BDSI from exercising any other rights it may have under this Agreement as a consequence of the lateness of any payment. 

4.11 All taxes levied on account of the payments accruing to a Party under this Agreement shall be paid by such Party for its own
account, including taxes levied thereon as income to such Party. If provision is made in applicable law or regulation for withholding on any payment due to the other Party under this Agreement, such tax shall be deducted from the payment made by a
Party (the “Paying Party”) to the other Party (the “Paid Party”) hereunder, shall be paid to the proper taxing authority by the Paying Party, and a receipt of payment of such tax shall be secured and promptly delivered to the
Paid Party. Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under any double taxation or similar agreement or treaty from time to time in force or in otherwise seeking the return,
refund, or credit of any such withheld amount as applicable. 
  

 17 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 4.12 During the Term and for a period of five years thereafter, or longer if and as
required in order for Kunwha to comply with Applicable Law, Kunwha shall keep complete and accurate records in sufficient detail to permit BDSI to confirm the completeness and accuracy of (i) the information presented in each Royalty Statement
and all payments due hereunder and (ii) the calculation of Net Sales. BDSI and any designee thereof shall have the right to audit and inspect such records pursuant to the terms of Section 13.12. 

5. COMMERCIALIZATION 

5.1 Kunwha, at its own expense, will be responsible for all sales and marketing activities related to the Licensed Product in the
Territory. 
 5.2 Kunwha agrees to use Commercially Reasonable Efforts to promote the sale, marketing, and distribution of, and
otherwise commercialize and sell, the Licensed Product in the Territory for all indications that have received Governmental Approval. Upon BDSI’s request, Kunwha shall provide BDSI with commercial, financial or other information that BDSI may
reasonably request relating to the marketing, sale or distribution of the Product. 
 5.3 Beginning on the date of First
Commercial Sale, Kunwha shall use Commercially Reasonable Efforts to deploy its sales representatives to sell the Licensed Product in the Territory, who will target physicians reasonably identified by Kunwha as potentially high volume prescribing
physicians for the Licensed Product. 
 5.4 No rights to the trademark ONSOLIS, BREAKYL, or any other trademarks, trade dress,
or logos used with respect to the Licensed Product outside the Territory are granted to Kunwha under this Agreement, and, notwithstanding anything to the contrary, BDSI shall not be required to include any such trademark, trade dress or logo on any
packaging or related materials concerning any Licensed Product supplied to Kunwha. Any trademark, logo, design and/or trade dress for the Licensed Products used by Kunwha, its Affiliates, or Sublicensees in the Territory shall be subject to
BDSI’s prior written approval, such approval not to be unreasonably withheld, comply with Applicable Laws, and not infringe or misappropriate the intellectual property rights of any Third Party. 

 

 18 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 6. COMPLIANCE 

6.1 Subject to Kunwha’s obligations upon termination pursuant to this Agreement, Kunwha shall, following final Governmental Approval
or Marketing Authorization by a given Competent Authority, be the holder and owner of such Marketing Authorization and Governmental Approval in the Territory. Kunwha agrees that neither it nor its Affiliates will do anything to recklessly,
negligently, or intentionally adversely affect any Marketing Authorization or Governmental Approval. 
 6.2 With respect to the
Licensed Product, Kunwha agrees, at its sole cost and expense, to maintain all Marketing Authorizations and Governmental Approvals throughout the Term including obtaining any supplemental applications, annual reports, variations or renewals thereof.

 6.3 After the Effective Date, Kunwha shall promptly provide BDSI a copy of any material correspondence or materials that it
receives from a Competent Authority regarding any Licensed Product. If such correspondence is not received in English, a summary in English of all material matters addressed thereby will be provided. 

6.4 Kunwha shall, at its sole cost and expense, be responsible for all post-Governmental Approval reporting of ADEs and Phase IV
surveillance in the Territory, if and as required by Competent Authorities. Kunwha shall provide BDSI with a copy of all safety-related correspondence with any Competent Authority within *** of its receipt or submission. 

6.5 Following Governmental Approval, Kunwha will be responsible for (i) maintaining the Company Core Safety Information
(“CCSI”), as included in the Company Core Data Sheet (“CCDS”), in the Territory and (ii) maintaining the CCSI, as included in the Package Insert/Prescribing Information (“PI”), in the United States. Kunwha will
also be responsible for submission of any safety-related supplemental applications for changes to any package insert or other labeling. 

6.6 Following Governmental Approval, Kunwha (or its agent) will maintain a pharmacovigilance database for the Licensed Product in the
Territory. The database will include all ADE reports from spontaneous sources, scientific literature, and post-marketing surveillance reports (serious) and SAE reports from clinical studies coming into the knowledge of Kunwha Pharmacovigilance
Department (or its agent). Spontaneous cases will include reports received from both healthcare professionals and consumers. AE data will be carried out in accordance with Kunwha’s (or its agent’s) SOPs and Kunwha will use WHO ADR
terminology. All reasonable assistance and access requested by either Party in responding to safety inquiries will be provided upon request. Information in Kunwha’s safety databases will be used by Kunwha to compile periodic safety update
reports (PSURs) to the KFDA (providing a waiver of the requirement to submit postmarketing periodic safety reports in the format described in the regulations has been granted) and other Competent Authorities and prepare safety-related supplemental
applications for changes in the package insert(s)/labelling for Licensed Product. 
  

 19 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 6.7 The Parties shall keep each other informed on all safety matters related to the
Licensed Product and on any information received from any source concerning any ADR coming to either Party’s knowledge with regard to the Licensed Product. 

6.8 Each Party is responsible for fulfilling its reporting obligations to the appropriate regulatory authorities with respect to the
Licensed Product in accordance with the applicable national laws and regulations of the different countries. 
 6.9
Independently of any national reporting requirements, the Parties shall in relation to the Licensed Product report to each other all SAEs from clinical trials with a reasonable suspicion of causal relationship to the administered study medication
and all serious spontaneously reported suspected ADRs within the first ***, but not later than *** after having come to a Party’s attention including a case description and medical causality assessment on the International Adverse Event Report
Form (CIOMS form) in English. If required, follow up will be carried out by the Market Authorization holder on all SARs (listed and unlisted) and non-serious unlisted ADRs in the Territory according to its own internal procedures, which shall be
commercially reasonable and consistent with industry standards. Non-serious ADRs in the Territory shall be followed up by Kunwha if there is a safety concern, and pregnancy and in utero reports will be followed up by Kunwha at the expected
due date. Reasonable attempts shall be made by Kunwha to obtain the required minimum information: identifiable patient, reporter, suspect drug, and AE. 

6.10 Life-threatening or fatal SAEs originating from clinical trials in the Territory with a reasonable suspicion of causal relationship
to the Licensed Product shall be reported by a Party to the other Party and, if and as required thereby, by the appropriate Party (as determined by Applicable Law) to appropriate Competent Authorities within ***, but not later than ***. In the case
of incomplete or insufficient data available, an initial report has to be issued meeting the time frame, followed by reasonably prompt follow up report(s). Any ADRs originated by either Party in the Territory are to be reported on CIOMS form as soon
as reasonably possible, but no later than *** after first receipt. Kunwha will report all other ADRs in tabular format (CIOMS line listings) within *** after the end of each calendar month. 

 

 20 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 6.11 In any case where a change in the risk-benefit-ratio of the Licensed Product
becomes evident or safety actions due to ADR seem to be necessary (e.g. change of the label, product information, special information/warnings to the medical profession, patients, authorities or Product Recall), the Parties hereto will inform each
other without delay and use commercially reasonable efforts to harmonize further measures as appropriate. Such exchange of information is realized through direct contacts between the responsible departments. Therefore, both Parties undertake to
inform each other on any change in the responsible persons, the address, telephone and fax-numbers in due time. If specific safety measures are to be taken in the Territory with respect to any Licensed Product, Kunwha will ensure the implementation
of such in the Territory within mutually agreed timeframes or according to regulatory obligations. 
 6.12 Regulatory inquiries
related to safety concerns for the Licensed Product received by either Party will be promptly forwarded to the other Party. The Parties shall work in good faith to develop a mutually agreeable response with respect to any such inquiry in the
Territory at least *** before the response is required. The aforementioned information shall be addressed to: 
 In case of BDSI:

 Director, Regulatory Affairs 

BioDelivery Sciences International, Inc. 
 801
Corporate Center Drive, Suite 210 
 Raleigh, North Carolina 27607 

USA 
 Tel.: 919-582-9050 

Fax: 919-582-9051 
 Email:
afinn@bdsinternational.com 
  

 21 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 In case of Kunwha: 

Noh Joon Park 
 Senior Manager, Business
Development Department 
 Kunwha Pharmaceutical Co., Ltd. 

Kunwha Bldg, 94, 
 Karak-Dong, Songpa-Gu, Seoul,
138-804, Korea 
 Tel.: 82-2-2047-7784 

Fax: 82-2-443-0587 
 Email: nopark@kunwha.com

 6.13 Kunwha will have the primary responsibility for reviewing the world-wide relevant scientific literature for any serious
and non-serious unlisted ADRs related to the Licensed Product in the Territory according to Applicable Laws. 
 6.14 Kunwha will
perform signal detection concerning the Licensed Product according to its own internal documented practices (as outlined in SOPs/guidelines), which shall be commercially reasonable and consistent with industry standards. Any conclusion raised from
the subsequent analysis revealing relevant safety concerns regarding the Licensed Product will be communicated to BDSI in due time or immediately if the conclusions affect the safety profile of the Licensed Product. 

6.15 Kunwha will be responsible for preparing the periodic reports to be submitted to Competent Authorities in the Territory (Periodic
Safety Update Reports (“PSURs”), Annual Safety Reports for clinical trials) in accordance with its own standard operating procedures (“SOPs”), which shall be commercially reasonable and consistent with industry standards, and
Applicable Laws. BDSI will, on Kunwha’s reasonable request, provide Kunwha with all data (e.g. CIOMS line listings for SAEs originating from BDSI’s clinical trials) in its possession, and which BDSI has the right to provide to Kunwha,
which may reasonably be required for regulatory report compilation in the Territory. 
 6.16 If, after the date of First
Commercial Sale, a Competent Authority in the Territory requires additional testing, modification or communication related to approved indications of any Licensed Product, then Kunwha shall, subject to BDSI’s prior written approval of any such
testing, modification, or communication, design any such testing, modification, or communication. BDSI shall, if and as agreed to by BDSI in writing, be responsible for any additional formulation or CMC work as required, at Kunwha’s cost, while
Kunwha shall be responsible for an additional pre-clinical and clinical testing and any other items required by such Competent Authority, at Kunwha’s cost, provided that Kunwha shall not initiate any such testing or other activities without
BDSI’s prior written consent. 
  

 22 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 6.17 Upon receipt of a written request, each Party shall provide reasonable assistance
to the other Party, in connection with such Party’s obligations pursuant to this Section, subject to reimbursement of all of its pre-approved out-of-pocket costs by the requesting Party. 

6.18 Kunwha and BDSI shall comply with all Applicable Laws in exercising their rights and performing their obligations under this
Agreement, including the provision of information by Kunwha and BDSI, to the extent in its possession, to each other necessary for BDSI and Kunwha to comply with any applicable reporting requirements. Each Party shall promptly notify the other Party
of any comments, responses or notices received from any applicable Competent Authorities, which relate to or may impact any Licensed Product or the sales and marketing of any Licensed Product, and shall promptly inform the other Party of any
responses to such comments, responses, notices or inspections and the resolution of any issue raised by any Competent Authorities with respect to any Licensed Product. 

7. SUPPLY 
 7.1
BDSI will be the exclusive supplier to Kunwha of the Product, and BDSI shall supply Product for commercial sale within the Territory exclusively to Kunwha, as described herein during the term of this Agreement. 

7.2 Subject to the terms of this Agreement, BDSI shall supply to Kunwha Product for use, sale, or distribution in the Territory. BDSI
shall be the sole and exclusive supplier of the Product to Kunwha during the term of this Agreement, and Kunwha shall purchase solely from BDSI all of its requirements for Product to be used, sold, or distributed in the Territory. Kunwha shall not
manufacture or have manufactured on its behalf, nor obtain from any Affiliate of Kunwha or any Third Party, any Product. BDSI shall be entitled to engage Third Parties as necessary to fulfill BDSI’s obligations under this Agreement with respect
to the supply of Product provided that BDSI shall continue to be responsible for such Third Party’s performance of BDSI’s obligations with respect to the supply of Product hereunder. 

7.3 The manner and style of the labeling and trade dress of the Licensed Product shall be as mutually agreed upon by the Parties in
writing consistent with this Agreement, and upon such mutual agreement shall be deemed part of the Product Specifications, subject to any future changes reasonably requested by Kunwha, agreed upon in writing by BDSI, and paid for by Kunwha. For the
avoidance of doubt, Kunwha shall be solely responsible for the contents of any product label and BDSI shall not be responsible in any manner, including but not limited to under any provision of this Agreement, for any error, mistake, violation of
any Applicable Law or any other problem with the content of the label unless BDSI does not follow label instructions provided by Kunwha in accordance with this Agreement. Any Kunwha-requested change or modification to a Product’s label or
packaging shall be subject to BDSI’s prior written approval of such change or modification. Kunwha shall reimburse BDSI for the reasonable total direct and indirect cost of any Product labels rendered obsolete by such change. 

 

 23 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 7.4 Kunwha may from time to time place, and BDSI will accept, written purchase orders
for batches of the Licensed Product and any other Products, as further described below and BDSI will use Commercially Reasonable Efforts to supply Products to Kunwha. However, Kunwha acknowledges both the inherent risk that one or more batches of
bulk or finished Products may be lost in production or shipment and that any of its orders for Products could be delayed until demand (of both Kunwha and BDSI’s other licensees) of the Products and similar products is reasonably sufficient to
justify BDSI’s production of any or all of the Products. All provisions of this Section 7 “Supply” regarding ordering and delivery of Products will be subject to the provisions contained in this Section 7.4 and Kunwha
specifically acknowledges BDSI’s ability to delay production and delivery of Products, or upon Kunwha’s written request provide to Kunwha products on a mutually agreeable timeline and pricing schedule that will be negotiated outside of the
terms of this Agreement. 
 7.5 To the extent Product Development requires Kunwha to conduct clinical trials in the Territory,
Kunwha may from time to time place, and BDSI will accept, binding written purchase orders for batches of Products to be used for clinical studies conducted by Kunwha under the Development Program (“Clinical Supply Orders”). The Parties
shall work together in good faith to establish the amounts of Products to be used in any clinical trial(s) to be conducted under the Development Program and establish a delivery schedule for such Products, subject to the Parties’ mutual written
agreement with respect thereto, and BDSI shall use commercially reasonable efforts to supply such Products to Kunwha in accordance with such schedule (such order, the “Initial Clinical Supply Order”). Clinical Supply Orders for subsequent
clinical trials (“Subsequent Clinical Orders”) shall be placed reasonably, but at least ***, in advance of the requested date of delivery subject to the terms of this Agreement. BDSI shall use Commercially Reasonable Efforts to deliver
according to the delivery schedule contained in any Subsequent Clinical Supply Order. Notwithstanding the foregoing, all delivery dates are targets only. No terms and conditions contained in any Clinical Supply Order, acknowledgment, invoice, bill
of lading, acceptance or other preprinted form issued by either Party shall be effective to the extent they are inconsistent with, modify or add to the terms and conditions contained herein. 

 

 24 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 7.6 Within *** following Kunwha’s submission of the initial application for
Governmental Approval to a Competent Authority in the Territory with respect to the Licensed Product, Kunwha shall provide BDSI with a Forecast of Kunwha’s requirements for Products for the *** following receipt of the anticipated Marketing
Authorization (including any required Pricing and Reimbursement Approvals). The Forecast shall be updated ***, until the date on which Kunwha places its first Order other than a Clinical Supply Order, at which time Forecasts shall be provided in
accordance with Section 7.7. Except as otherwise provided herein, all Forecasts made hereunder shall be nonbinding and made to assist BDSI in planning its production and Kunwha in planning marketing and sales. 

7.7 For all Products *** before the beginning of each Calendar Quarter, give BDSI (i) its Order for the Products to be delivered to
Kunwha during that Calendar Quarter and (ii) a Forecast for the *** Calendar Quarters. BDSI shall not be obligated to accept any Order for a Calendar Quarter *** the amounts forecast for that Calendar Quarter in the previous Forecast. However,
BDSI shall make commercially reasonable efforts, but not be obligated, to also deliver such exceeding quantities. Kunwha may request amendment to an Order *** Order is given and BDSI shall use its commercially reasonably efforts to accept such
amendment provided, however, BDSI shall not be obligated to accept such amendment if quantities specified in the Order are increased by more than ***, cause the Product scheduled for delivery in a Calendar Quarter to exceed *** amounts previously
included in the Forecast for that Calendar Quarter, or are decreased by more than *** to the original Order. However, BDSI shall make commercially reasonable efforts, but not be obligated, to also deliver any quantities exceeding the aforementioned
limitations. No terms and conditions contained in any Order, acknowledgment, invoice, bill of lading, acceptance or other preprinted form issued by either Party shall be effective to the extent they are inconsistent with, modify or add to the terms
and conditions contained herein. Provided that BDSI continuously fails ***, BDSI shall compensate all the damages incurred therein by Kunwha. 
  

 25 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 7.8 BDSI shall provide to Kunwha the Licensed Products of which shelf life is at least
*** from receipt. Kunwha shall be entitled at its option to reject such part of any delivery of the Product which does not comply with the shelf life stated above and the Product Specifications, provided that Kunwha shall be deemed to have
accepted any delivery of the Product unless it gives BDSI notice of its rejection within *** of delivery, or in case of a latent defect, within *** after the date Kunwha could have reasonably discovered such latent defect, but in no event ***. BDSI
shall, at BDSI’s option, promptly replace (without additional cost) or refund to Kunwha the amount actually paid by Kunwha to BDSI with respect to any such Products rejected by Kunwha which do not comply with the Product Specifications.

 7.9 If, with respect to any Product which have been replaced and/or for which the amount actually paid by Kunwha therefore
has been refunded is, following investigation, found by reasonable, independent, neutral, third party laboratory analysis pursuant to generally-accepted scientific methods, to have complied with Product Specifications, Kunwha shall: accept those
Products as part of the next order and, if no Order will be placed before the termination of this Agreement, pay BDSI the applicable amount therefor pursuant to this Agreement, and refund any additional amount paid by BDSI to Kunwha with respect
thereto. 
 7.10 BDSI may, in its sole discretion, contract with Third Parties for the manufacture or supply of Products
hereunder as it may determine necessary to enable it to satisfy its obligations hereunder. For purposes of clarification but not limitation, the performance of any of BDSI’s obligations hereunder by any such Third Parties shall be deemed to
satisfy such obligations of BDSI. 
 7.11 Consistent with Section 7.4, Kunwha agrees to maintain an inventory of Product
reasonably sufficient, consistent with industry standards, to supply at *** at all times. Should BDSI provide *** of Licensed Product Ordered by Kunwha according to Section 7.7, Kunwha shall not be breach of this section when utilizing its
inventory of Licensed Product to make-up any shortfall not supplied by BDSI. 
 7.12 BDSI warrants that all Product supplied
pursuant to this Agreement shall on the date of delivery materially comply with the Product Specifications. Changes to the Product Specifications may be made as (a) reasonably requested by Kunwha and agreed upon in writing by BDSI,
(b) necessary to conform to the regulatory requirements necessary to obtain and maintain Governmental Approvals and agreed upon in writing by BDSI, or (c) reasonably requested by BDSI or otherwise necessary to enable BDSI and any Third
Party manufacturing Products on behalf of BDSI to comply with the legal and regulatory requirements applicable to Products outside the Territory (including those of any regulatory filing or approval outside the Territory). Replacement or refund, as
elected by BDSI in its sole discretion, shall be Kunwha’s sole remedy for breach of such warranty unless such breach is the result of BDSI’s gross negligence or willful misconduct. 

 

 26 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 7.13 BDSI shall, as soon as reasonably possible, provide written notice of any
significant changes proposed by BDSI to the Product or method of manufacture of the Product. BDSI shall use Commercially Reasonable Efforts to ensure that the time for implementing such changes shall provide Kunwha a reasonable opportunity to obtain
the relevant Governmental Approvals prior to such implementation. 
 7.14 BDSI shall provide Kunwha with certificates of quality
assurance and quality control analysis with respect all deliveries of the Product, as customary in the industry, and with manufacturing and export documents as necessary for (i) import of the Product and (ii) compliance with all applicable
regulatory requirements. BDSI shall keep complete, accurate and authentic accounts, notes, data and records of the work performed by it under this Agreement and shall maintain complete and adequate records pertaining to the methods and facilities
used by it for the manufacture, processing, testing, packing, labeling, holding and distribution of Product in accordance with the applicable regulations. 

7.15 BDSI shall retain (or cause any relevant Third Party contractors to retain), at BDSI’s cost, a reasonably sufficient quantity
of each batch of Product to perform quality control testing. BDSI shall maintain such samples of each batch in a reasonably suitable storage facility *** approved shelf life of the Product, or such longer period as may be required under applicable
laws, rules, and regulations. Portions of all such samples shall be made reasonably available for testing by Kunwha, at Kunwha’s expense, upon request. 

7.16 BDSI shall maintain (or shall use commercially reasonable efforts to ensure that any relevant Third Party contractors maintain) all
records as necessary to comply with manufacturing regulations imposed by any regulatory authority. 
 7.17 BDSI shall be
responsible for assisting Kunwha in investigating complaints and “Lack of Effect” reports relating to the manufacture and/or packaging of Product which are supplied by BDSI. BDSI shall, as reasonably directed by Kunwha, evaluate the nature
of the complaint and document the evaluation on Product manufactured and/or packaged by BDSI for Kunwha. This evaluation may include but is not limited to providing assessments of: (i) returned sample(s) (where appropriate); (ii) retained
samples; (iii) the manufacturing process; (iv) release tests; (v) receiving tests; (vi) complaint history; and (vii) conclusion/summary. The documented evaluation of the complaint will be provided by BDSI to Kunwha within
*** from the date of BDSI’s receipt of the complaint. BDSI’s costs and expenses related to any assistance or other actions undertaken by BDSI pursuant to this Section 7.17 shall be reimbursed by Kunwha within *** of an invoice
therefor from BDSI, except to the extent any such “Lack of Effect” reports result from BDSI’s negligence, intentional misconduct, or material breach of its obligations under this Agreement, in which case BDSI shall bear such costs and
expenses. 
  

 27 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 7.18 Delivery of the Product shall be effected *** at which time all risk of loss and
damage to the Product shall pass to Kunwha and Kunwha shall carry out all customs clearances necessary for the shipment of the Product into the Republic of Korea at its own expense. BDSI should provide Kunwha with all necessary documents in order
that Kunwah may obtain the necessary import approval from the Korean FDA ***.  
 7.19 Prior to shipment, BDSI shall
perform release testing in any manner required by the Product Specifications, if specifically described therein, and all applicable laws, rules and regulations, including the Governmental Approvals. 

7.20 Kunwha shall pay the amounts due under Sections 4.4 and 4.5 for all Product delivered to it under this Agreement within *** of its
receipt of an invoice for such Products. If Kunwha refuses or fails to take delivery of Product ordered under this agreement at the time stated for delivery in the applicable Order, BDSI shall be entitled, at its discretion, to invoice Kunwha in
full for the amounts due hereunder for such Product and to store Product at Kunwha’s cost, which shall be commercially reasonable and include insurance with coverage in amounts and types reasonably sufficient to cover the loss of such Product.
Any amounts due under the foregoing sentence shall be paid by Kunwha within *** of its receipt of an invoice concerning such amounts. 

8. PRODUCT RECALL 

8.1 If at any time or from time to time, a Competent Authority requests Kunwha to conduct a Product Recall of any Product in the Territory
or if a voluntary Product Recall of any Product in the Territory is contemplated by Kunwha, Kunwha shall immediately notify BDSI in writing, and Kunwha will conduct such Product Recall in as reasonable, prudent, and expeditious a manner as possible
to preserve the goodwill and reputation of the Product and the goodwill and reputation of the Parties. 
 8.2 Kunwha shall not
carry out a voluntary Product Recall in the Territory with respect to any Product without the prior written approval of BDSI, such approval not to be unreasonably withheld (for the avoidance of doubt, any Product Recall that is reasonably deemed
necessary in order to avoid serious personal injury shall not be considered as a voluntary Product Recall, provided that Kunwha shall provide BDSI the opportunity to advise and comment with respect to any such Product Recall prior to its execution);
and the Parties shall reasonably cooperate, in the conduct of any Product Recall for such Product in the Territory. Product Recall cost shall be borne in accordance with Section 8.5. 

 

 28 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 8.3 Notwithstanding the foregoing, Kunwha may, without BDSI’s prior consent,
immediately affect any Product Recall (A) resulting from any death or life-threatening adverse event associated with any Product or (B) required to comply with any regulatory or legal requirements, guidelines, directives, orders, or
injunctions with respect to any Product. In the event Kunwha does not undertake such a Product Recall in a reasonable period of time, BDSI shall be entitled to do so without Kunwha’s prior written consent. 

8.4 Kunwha shall have the right to control and/or conduct any Product Recall in the Territory, subject to the terms of this Agreement.
The Product Recall shall be the responsibility of Kunwha and their Affiliates and shall be carried out by Kunwha or its Affiliates in as reasonable, prudent, and expeditious a manner as possible to preserve the goodwill and reputation of the
Licensed Product and the goodwill and reputation of the Parties. Kunwha shall maintain records of all sales and distribution of Product and customers in the Territory sufficient to reasonably adequately administer a Product Recall, for the period
required by Applicable Law, and make such records available to BDSI or any designee thereof immediately upon request. 
 8.5
Kunwha shall bear any and all costs and expenses related to any Product Recall in the Territory (including but not limited to any Product Recall undertaken by BDSI in accordance with Section 8.3), provided that, notwithstanding the foregoing,
BDSI shall bear any such costs and expenses to the extent such Product Recall is conclusively demonstrated by Kunwha to be reasonably attributable to BDSI’s negligence, intentional misconduct, or supply of Licensed Products that do not
materially conform to the Product Specifications. 
 8.6 Throughout the duration of this Agreement and with respect to all
Product the Parties shall immediately notify each other of any information a Party receives regarding any threatened or pending action, inspection or communication by or from a concerned Competent Authority which may affect the safety or efficacy
claims of the Licensed Product or the continued marketing of the Licensed Product. Upon receipt of such information during the duration of this Agreement, Kunwha shall not take any action whatsoever without BDSI’s prior review and approval,
such approval shall not be unreasonably withheld. 
  

 29 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 9. TERM AND TERMINATION 

9.1 This Agreement shall commence as of the Effective Date and shall expire at the end of the Term (unless mutually otherwise agreed
between the Parties six (6) months prior to expiration) or terminate upon on the earlier termination of this Agreement as described herein. 

9.2 Either Party may terminate this Agreement prior to the expiration of the Term upon the occurrence of any of the following:

 (i) Upon or after the cessation of operations of the other Party or the bankruptcy, insolvency, dissolution or
winding up of the other Party (other than dissolution or winding up for the purposes or reconstruction or amalgamation); or 

(ii) Upon or after the breach of any material provision of this Agreement by the other Party if the breaching Party has
not cured such breach within *** after written notice thereof by the non-breaching Party. 
 9.2A Kunwha may terminate this
Agreement prior to the expiration of the Term upon the occurrence of any of the following: 
 (i) *** advance
written notice to BDSI; 
 (ii) the failure to obtain KFDA approval;(iii) the failure by BDSI to supply the ordered Licensed
Products according to section 7. 
 9.3 BDSI may, by written notice to Kunwha, and in addition to any termination rights
provided in Section 9.2, terminate this Agreement upon the occurrence of any of the following: 
 (i) Upon
the failure by Kunwha to pay any amounts due pursuant to Section 4.1, 4.2, 4.4, or 4.5 on the due date established therefor under this Agreement. 

(ii) Upon the loss, revocation, suspension, termination, or expiration of Kunwha’s license to sell narcotics in the
Territory, if Kunwha fails to take the actions necessary to reinstate such license within *** of such loss, revocation, suspension, termination, or expiration. 

(iii) Upon the loss, revocation, suspension, termination, or expiration of the Governmental Approval to sell the Licensed
Product in the Territory, if Kunwha fails to take the actions necessary to reinstate such license within *** of such loss, revocation, suspension, termination, or expiration. 

 

 30 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 (iv) Upon the occurrence of any material misrepresentation or omission
in any Royalty Statement, which misrepresentation or omission is caused by Kunwha’s willful misconduct, gross negligence, or bad faith. 

9.4 All of the non-breaching Party’s remedies with respect to a breach of this Agreement shall be cumulative, and the exercise of
one remedy under this Agreement by the non-defaulting Party shall not be deemed to be an election of remedies. These remedies shall include the non-breaching Party’s right to sue for damages for such breach without terminating this Agreement.

 9.5 BDSI shall not terminate this Agreement before the expiration of the Term except any occurrence set forth in Sections 9.2
or 9.3. 
 (a) Upon any termination or expiration of this Agreement, Kunwha, to the extent requested by BDSI in writing within
*** of such termination or expiration, hereby grants and assigns to BDSI all right, title and interest in, to or under all Governmental Approvals, the Clinical Documentation, the Results, the Marketing Authorizations, all intellectual property
rights associated therewith (including copyright) that are not otherwise required to be assigned to BDSI as required by Section 3, and all other data, reports, studies, analysis or similar items created or obtained by or on behalf of Kunwha or
its Affiliates in connection with the development, marketing or commercialization of the Licensed Product in the Territory free, clear of any and all liens, claims, and encumbrances. Kunwha shall deliver all such items, including any copies thereof,
to BDSI within *** of BDSI’s request therefor and agrees to take such actions as BDSI may reasonably request in order to effectuate the assignment set forth in this paragraph. 

(b) In the case of any expiration (but not early termination) of this Agreement, or any termination of this Agreement by Kunwha pursuant
to Section 9.2(ii), the Parties shall use commercially reasonable efforts to negotiate in good faith financial consideration to be paid by BDSI for the assignments described in Section 9.5(a), which consideration shall be commercially
reasonable, and the above-referenced assignments shall not take place until the Parties have agreed in writing on such financial consideration (or the amount of such consideration has been determined pursuant to Section 13.5, to the extent
contemplated in the following sentence). In the event the Parties are unable to reach agreement on the amount of such consideration within *** of BDSI’s request for any assignment subject to this Section 9.5(b), BDSI shall have the option
of rescinding such request for such assignments or having the dispute resolution process described in Section 13.5 determine the financial consideration to be paid by BDSI to Kunwha for such assignments. If BDSI does not provide written notice
indicating which option it wishes to elect pursuant to the preceding sentence within *** of the expiration of the above-referenced *** period, BDSI shall be deemed to have rescinded its request to have such materials and assets assigned to it.

  

 31 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 9.6 Upon any termination or expiration of this Agreement, Kunwha shall use its best
efforts, if and as requested by BDSI, to have assigned to BDSI any contracts entered into by Kunwha concerning the development, marketing, distribution, or sale of the Licensed Product in the Territory. 

9.7 Upon termination or expiration of this Agreement, as elected by Kunwha, Kunwha (and/or its Affiliates, if and as applicable) shall
(i) sell remaining inventory of Products to BDSI at the purchase price paid by Kunwha or its Affiliates for such inventory under Section 4.4 or 4.5 (ii) destroy remaining inventory of Product in accordance with Applicable Law,
providing BDSI with proof of destruction in writing sufficient to comply with Applicable Law or (iii) sell remaining inventory of Products any customer for *** limited period after the assignment. Any sales of Products made by Kunwha to BDSI
pursuant to clause (i) in the preceding sentence shall be made by Kunwha within *** of Kunwha’s receipt of BDSI’s written notice electing to make such purchase, and shall be shipped to BDSI appropriately packaged and stored. All
transportation costs in connection with such sale, including without limitation, insurance, freight and duties, shall be paid by Kunwha under the Section 9.2A or shall be paid by BDSI under the Section 9.3. Amounts owed by BDSI to Kunwha
pursuant to this Section 9.7 for the any Products sold to BDSI shall be paid by BDSI within *** after receipt by BDSI of an appropriately detailed invoice from Kunwha for the amount so owing to it by BDSI under this Section 9.7.

 9.8 Except as otherwise provided in this Agreement, expiration or termination of this Agreement shall not relieve the Parties
of any obligation accruing prior to such expiration or termination. Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under Sections 2.2, 2.6 (first sentence), 2.10, 2.11, 3.5, 3A7, 4, 6, 8, 9, 10,
11, 12 and 13 shall survive expiration or termination of this Agreement. 
 10. INDEMNIFICATION AND INSURANCE 

10.1 BDSI shall indemnify and hold Kunwha, its Affiliates, and their respective employees, directors and officers, harmless from and
against any liabilities or obligations, damages, losses, claims, encumbrances, costs or expenses (including attorneys’ fees) (any or all of the foregoing herein referred to as “Loss”) insofar as a Loss or actions in respect thereof
occurs subsequent to the Effective Date arises out of a claim by a Third Party based on or resulting from: (a) any misrepresentation or breach of any of the warranties, covenants or agreements made by BDSI in this Agreement or
(b) BDSI’s negligence or intentional misconduct. BDSI’s obligations to indemnify Kunwha hereunder shall not apply to the extent any such Loss arises out of or is based on any (a) inactions or actions of Kunwha or its Affiliates
for which Kunwha is obligated to indemnify BDSI or (b) negligence or intentional misconduct of Kunwha or its Affiliates. 
  

 32 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 10.2 Kunwha shall indemnify and hold BDSI and its Affiliates, and their respective
employees, directors and officers of any of the foregoing, harmless from and against any Loss insofar as such Loss or actions in respect thereof occurs subsequent to the Effective Date and arises out of or is based upon a claim by a Third Party
based on or resulting from (a) any misrepresentation or breach of any of the warranties, covenants or agreements made by Kunwha in this Agreement, (b) Kunwha’s or its Affiliates’ development, use, marketing, manufacture, sale,
distribution, promotion, handling, or storage of any Products, (c) any product liability claim brought by any Third Party due to the use of any Product sold or distributed by or on behalf of Kunwha or any Affiliate thereof in the Territory, or
(d) any alleged copyright or trademark infringement, or similar action, involving the labeling, packaging, marketing or promotional materials, logos, trademarks, trade dress, or advertising concerning any Product (including BDSI’s use of
any of the foregoing in its manufacture and supply of Products to Kunwha), except to the extent any such Loss results from (i) any misrepresentation or breach of any of the warranties, covenants or agreements made by BDSI in this Agreement or
(ii) BDSI’s negligence or intentional misconduct. Kunwha’s obligations to indemnify BDSI hereunder shall not apply to the extent any such Loss arises out of or is based on the negligence or intentional misconduct of BDSI.
Notwithstanding the foregoing, in the event that any product liability claim is brought by any Third Party due to the use of any Product in the Territory, BDSI shall provide all reasonable assistance in the defense or settlement of such claim, at
Kunwha’s expense, provided that and where such claim is caused by or attributable to any negligent act or omission, intentional misconduct, violation of Applicable Law, or breach of warranties hereunder by BDSI, such assistance shall be at
BDSI’s expense, provided that the foregoing shall be subject to any applicable indemnification obligation of BDSI with respect to any such claim under Section 10.1. 

10.3 No claim for indemnification hereunder shall be valid unless notice of the matter which may give rise to such claim is given in
writing by the indemnitee (the “Indemnitee”) to the persons against whom indemnification may be sought (the “Indemnitor”) as soon as reasonably practicable after such Indemnitee becomes aware of such claim, provided that,
notwithstanding the foregoing, the failure to notify the Indemnitor shall not relieve the Indemnitor from any liability except to the extent that such failure to notify actually adversely impacts the Indemnitor’s ability to defend such claim.
Such notice shall state that the Indemnitor is required to indemnify the Indemnitee for a Loss and shall specify the amount of Loss and relevant details thereof. The Indemnitor shall notify Indemnitee no later than *** from such notice of its
intention to assume the defense of any such claim. In the event the Indemnitor fails to give such notice within that time the Indemnitor shall no longer be entitled to assume such defense. 

 

 33 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 10.4 The Indemnitor shall at its expense, have the right, subject to the limitations of
this Section 10.4, to settle and defend, through counsel reasonably satisfactory to the Indemnitee, any action which may be brought in connection with all matters for which indemnification is available. In such event the Indemnitee of the Loss
in question and any successor thereto shall permit the Indemnitor full and free access to its books and records and otherwise fully cooperate with the Indemnitor in connection with such action; provided that this Indemnitee shall have the right
fully to participate in such defense at its own expense. The defense by the Indemnitor of any such actions shall not be deemed a waiver by the Indemnitor of its right to assert a claim with respect to the responsibility of the Indemnitor with
respect to the Loss in question. The Indemnitor shall not settle or compromise any claim against the Indemnitee without the prior written consent of the Indemnitee, provided that such consent shall not be unreasonably withheld. No Indemnitee shall
pay or voluntarily permit the determination of any liability which is subject to any such action while the Indemnitor is negotiating the settlement thereof or contesting the matter, except with the prior written consent of the Indemnitor, which
consent shall not be unreasonably withheld. If the Indemnitor fails to give Indemnitee notice of its intention to defend any such action as provided herein, the Indemnitee involved shall have the right to assume the defense thereof with counsel of
its choice, at the Indemnitor’s expense, and defend, settle or otherwise dispose of such action. With respect to any such action which the Indemnitor shall fail to promptly defend, the Indemnitor shall not thereafter question the liability of
the Indemnitor hereunder to the Indemnitee for any Loss (including counsel fees and other expenses of defense). 
 10.5 Kunwha
shall, at its sole cost and expense, obtain and keep in force comprehensive general liability insurance, including any applicable self-insurance coverage, with bodily injury, death and property damage including contractual liability and product
liability coverage, of the types and in amounts which are reasonable and customary in the pharmaceutical industry for companies of comparable size and activities. 

 

 34 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 11. REPRESENTATIONS AND WARRANTIES 

11.1 As of the Effective Date, each Party hereby represents and warrants that such Party is duly organized and validly existing under the
laws of the jurisdiction of its organization and has full power and authority to enter into this Agreement and the transactions contemplated hereby and to carry out the provisions hereof. 

11.2 As of the Effective Date, each Party hereby represents and warrants that such Party is duly authorized to execute and deliver this
Agreement and to perform its obligations hereunder. 
 11.3 As of the Effective Date, each Party hereby represents and warrants
that this Agreement is a legal and valid obligation binding upon it and is enforceable in accordance with its terms, except that the enforcement of the rights and remedies created hereby is subject to bankruptcy, insolvency, reorganization and
similar laws of general application affecting the rights and remedies of creditors and that the availability of the remedy of specific performance or of injunctive relief is subject to the discretion of the court before which any proceeding therefor
may be brought. As of the Effective Date, each Party represents and warrants that the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it
is a party or by which it may be bound, violate any law or regulation of any court, governmental body or administrative or other agency having authority over it, including, with respect to the representations and warranties made by Kunwha under this
Section 11.3, any competition, antitrust, or similar laws, statutes, regulations, or directives in the Territory. 
 11.4
As of the Effective Date, each Party hereby represents and warrants to the other Party that there is no action, suit or proceeding pending against or affecting, or, to the knowledge of either Party, threatened against or affecting that Party, or any
of its assets, before any court or arbitrator or any governmental body, agency or official that would, if decided against either Party, have a material adverse impact on the business, properties, assets, liabilities or financial condition of that
Party (that are not already reflected in that Party’s respective financial statements as filed with the Securities and Exchange Commission (or foreign equivalent thereof) or otherwise made public or provided to the other Party) and which would
have a material adverse effect on that Party’s ability to consummate the transactions contemplated by this Agreement. 
  

 35 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 11.5 EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NOTHING HEREIN SHALL BE CONSTRUED
AS A REPRESENTATION OR WARRANTY BY BDSI TO KUNWHA THAT THE LICENSED TECHNOLOGY IS NOT INFRINGED BY ANY THIRD PARTY, OR THAT THE PRACTICE OF SUCH RIGHTS DOES NOT INFRINGE ANY INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. NEITHER PARTY MAKES ANY
WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE COMMERCIAL UTILITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF ANY LICENSED PRODUCT 

11.6 EXCEPT WITH RESPECT TO THE INDEMNIFICATION PROVIDED HEREUNDER, CLAIMS OF PATENT INFRINGEMENT, OR BREACHES OF CONFIDENTIALITY,
NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, EXEMPLARY, CONSEQUENTIAL, INDIRECT, OR PUNITIVE DAMAGES (AS SUCH TERMS ARE DEFINED IN BLACK’S LAW DICTIONARY, SIXTH EDITION) IN CONNECTION WITH THIS AGREEMENT OR ANY
LICENSE GRANTED HEREUNDER. 
 11.7 BDSI represents and warrants that (A) it has and shall maintain during the Term of this
Agreement (i) an exclusive license to or ownership or control of, as applicable, the Licensed Technology, and any other intellectual property rights which are the subject of Kunwha’s licenses under this Agreement, and (ii) the right
to grant the licenses described in this Agreement, and (B) the grant of such licenses by BDSI will not conflict with the terms of any existing agreement of BDSI concerning the Licensed Technology. 

11.8 BDSI represents and warrants that (i) the licenses granted to Kunwha hereunder comprise, to BDSI’s knowledge as of the
Effective Date, all intellectual property rights, other than rights to any trademarks, tradedress, or logos Kunwha wishes to use in the exercise of its rights hereunder, reasonably necessary for Kunwha to use and sell the Licensed Product as
contemplated by this Agreement. BDSI covenants that it will not, without Kunwha’s prior written consent, amend any agreement with a Third Party in a manner which would materially and adversely affect Kunwha’s rights hereunder. 

12. COVENANTS 

12.1 Each Party covenants and agrees that it shall permit the other Party (or any Third Party granted such rights under this Agreement) to
exercise such inspection rights as set forth in this Agreement. 
  

 36 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 12.2 Kunwha covenants and agrees that, as between Kunwha and BDSI, Kunwha shall be
responsible for the cost and implementation of marketing, sales, promotional and related activities concerning the marketing, sale and promotion of the Licensed Product in the Territory. BDSI shall, at Kunwha’s expense, provide any materials,
documents and information supporting Kunwha’s marketing sales, promotional and related activities upon Kunwha’s request to the extent BDSI has (i) such materials, documents, and information in its possession and (ii) has the
legal right, without breach of any other contractual or legal obligation BDSI may have, to provide such materials, documents and information to Kunwha. 

12.3 Each of Kunwha and BDSI shall cause its respective Affiliates to comply with all obligations of such Affiliates under this
Agreement. Each Party shall be responsible and liable for such Party’s Affiliates performance of such Party’s obligations hereunder and compliance with the terms of this Agreement, and any breach of the terms of this Agreement by any
Affiliate of a particular Party shall be deemed a breach of this Agreement by such Party. 
 12.4 Kunwha covenants and agrees
that it shall comply with all Applicable Laws affecting the use, possession, distribution, advertising and all forms of promotion in connection with the sale and distribution of the Licensed Product and other Products in the Territory.
Notwithstanding anything to the contrary, any failure of Kunwha, any Affiliate thereof, to adhere to any Applicable Laws in any country or supranational jurisdiction of the Territory concerning the handling of narcotics which materially adversely
affects the future manufacture, use, shipment, handling, sale, marketing, or distribution of fentanyl (or any product incorporating fentanyl) shall be deemed a material breach of this Agreement entitling BDSI, subject to prior notice and, to
terminate this Agreement pursuant to Section 9.3 in respect of such country or supranational jurisdiction. 
 12.5 Kunwha
covenants and agrees that, except as otherwise specified in this Agreement, Kunwha shall, following receipt of a Governmental Approval, have the obligation and responsibility for and shall make any and all necessary reports to each Competent
Authority with respect to the Licensed Product subject to such Governmental Approval and shall provide BDSI with a complete copy of any such report simultaneously with its submission of the report to each Competent Authority; if any such report is
submitted to the appropriate Competent Authority in a language other than English, Kunwha shall also provide BDSI with a summary of the material matters addressed in such report in English. Kunwha covenants and agrees that, except as otherwise
specified in this Agreement, Kunwha shall, if relevant, have the obligation and responsibility for and shall make any and all necessary reports in respect of the safe and lawful handling of the Licensed Product as a narcotic substance to each
Competent Authority, and shall provide BDSI with a complete copy of any such report simultaneously with the submission of the report to each Competent Authority; if any such report is submitted to the appropriate Competent Authority in a language
other than English, Kunwha shall also provide BDSI with a detailed summary of the material matters addressed in such report in English. 
  

 37 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 12.6 Upon the terms and subject to the conditions hereof, each of the Parties hereto
shall use its Commercially Reasonable Efforts to (a) take, or cause to be taken, all appropriate action and do, or cause to be done, all things necessary, proper or advisable under Applicable Law or otherwise to consummate and make effective
the transactions contemplated by this Agreement, (b) obtain from Competent Authorities any consents, licenses, permits, waivers, approvals, authorizations or orders required to be obtained or made by the Parties in connection with the
authorization, execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement. The Parties hereto shall cooperate with each other in connection with the making of all necessary filings, and any other
required submissions, with respect to this transaction under (i) the United States’ Securities Exchange Act of 1934, as amended and the United States’ Securities Act of 1933, as amended, and the rules and regulations thereunder and
any other applicable securities laws and (ii) any other applicable laws, rules, or regulations, including by providing copies of all such documents to the other Party’s counsel (subject to appropriate confidentiality restrictions) prior to
filing and, if requested, by accepting all reasonable additions, deletions or changes suggested in connection therewith. 
 12.7
During the Term, neither Kunwha, BDSI, nor any Affiliate of either of the foregoing shall, directly or indirectly, enable or contract with any Third Party to develop, manufacture, market, sell or distribute any Competing Product for commercial sale
as a human therapeutic product in the Territory or itself develop, manufacture, market, sell or distribute any Competing Product for commercial sale as a human therapeutic product in the Territory, provided that, notwithstanding the foregoing, in
the event that any Third Party acquires all or substantially all of the stock, assets, or business of BDSI or Parent (or all or substantially all of the assets or business of either of the foregoing related, in either case, to this Agreement) or
otherwise obtains control of BDSI or Parent (with “control”, for purposes of this Section 12.7, having the meaning set forth in Section 1.4), this Section 12.7 shall not apply to BDSI, Parent, any Affiliate of BDSI or
Parent, or such Third Party with respect to any products manufactured, marketed, sold, distributed, or under development by or on behalf of such Third Party or any affiliate or subsidiary thereof prior to such acquisition. 

 

 38 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 12.8 Kunwha shall not, without the prior written consent of BDSI, such consents not to
be unreasonably withheld, sell, license, encumber or otherwise transfer to a third party any rights in Governmental Approvals, the Development Documentation, the Results, the Marketing Authorizations, or any intellectual property rights associated
therewith (including copyright and trademark). 
 13. MISCELLANEOUS 

13.1 During the Term and for a period of five years thereafter, each Party shall maintain all Confidential Information of the other Party
as confidential and shall not disclose any such Confidential Information to any Third Party or use any such Confidential Information for any purpose, except: (a) as expressly authorized by this Agreement, (b) as required by law, rule,
regulation or court order (provided that the disclosing Party shall first notify the other Party, shall use Commercially Reasonable Efforts to obtain confidential treatment of any such information required to be disclosed, and shall disclose only
the minimum information required to be disclosed in order to comply), (c) to its Affiliates, employees, agents, consultants and other representatives to accomplish the purposes of this Agreement, or, in the case of BDSI, (d) under
conditions of confidentiality to any licensors, licensees, sublicensees, or contractors of BDSI or any Affiliate thereof with respect to any BEMA-based products. Each Party may use such Confidential Information only to the extent required to
accomplish the purposes of this Agreement or, in the case of BDSI, to satisfy any obligations to any licensor, licensee, sublicense or contractor of BDSI or any Affiliate thereof with respect to any BEMA-based product. Each Party shall use at least
the same standard of care as it uses to protect its own Confidential Information (but not less than a reasonable standard of care) to ensure that its Affiliates, employees, agents, consultants and other representatives do not disclose or make any
unauthorized use of the other Party’s Confidential Information. Each Party shall promptly notify the other Party upon discovery of any unauthorized use or disclosure of the other Party’s Confidential Information. 

13.2 Neither Party shall release to any Third Party or publish in any way any non-public information with respect to the terms of this
Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld. Notwithstanding the foregoing a Party may disclose the terms of this Agreement to potential investors, lenders, investment bankers and
other financial institutions of its choice solely for purposes of financing the business operations of such Party. Nothing contained in this paragraph shall prohibit either Party from filing this Agreement as required by the rules and regulations of
the Securities and Exchange Commission, national securities exchanges (including those located in countries outside of the United States) or the Nasdaq Stock Market; provided the disclosing Party discloses only the minimum information required to be
disclosed in order to comply with such requirements, including requesting confidential treatment of this Agreement (after reasonable consultation with the other Party) and filing this Agreement in redacted form. The Parties agree to cooperate with
respect to requests for confidential treatment to be submitted to the Securities and Exchange Commission or any similar foreign authority with respect to certain portions of this Agreement and any redactions thereof for such purposes. 

 

 39 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 13.3 Except as explicitly contemplated by this Agreement, neither this Agreement nor any
rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that either Party may assign
this Agreement and its rights and obligations hereunder without the other Party’s consent (a) in connection with the transfer or sale of all or substantially all of the business of such assigning Party to which this Agreement relates to a
Third Party, whether by merger, sale of stock, sale of assets or otherwise, or (b) to any of its Affiliates. Notwithstanding the foregoing, any such assignment to an Affiliate shall not relieve the assigning Party of its responsibilities for
performance of its obligations under this Agreement, so long as such Affiliate remains an Affiliate of the assigning Party. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the
successors and permitted assigns of the Parties. Any purported assignment not in accordance with this Agreement shall be void. 

13.4 Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or breached this
Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including, but not limited to, fire, floods,
embargoes, terrorism, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental authority or the
other Party, or for any other reason which is completely beyond the reasonable control of the Party (collectively a “Force Majeure”); provided that the Party whose performance is delayed or prevented shall continue to use good faith
diligent efforts to mitigate, avoid or end such delay or failure in performance as soon as practicable. 
 13.5 This Agreement
shall be governed by and construed under the state laws of the State of New York, without reference to its conflicts of laws principles. All disputes arising under or in connection with this agreement shall be finally settled by binding arbitration,
initiated by either Party on *** notice to the other Party, under the Rules of Arbitration of the International Chamber of Commerce (“ICC”), applying the laws of the State of New York, without regards to its conflicts of law provisions,
before three (3) independent, neutral arbitrators experienced in the pharmaceutical industry. The place of arbitration shall be New York, New York in case arbitration is initiated by Kunwha or Seoul, Republic of Korea in case arbitration is
initiated by BDSI. Kunwha and BDSI shall each be entitled to select one (1) such arbitrator, with the two such arbitrators so selected selecting the third such arbitrator. In the event either Party fails to select its arbitrator within such ***
period, the arbitrator selected by the other Party within such *** period shall be entitled to select such arbitrator. The arbitration shall be conducted in English. The decision of the arbitrators will be final and binding on the Parties, and any
decision of the arbitrators may be enforced in any court of competent jurisdiction. Notwithstanding the foregoing, any Party may seek injunctive, equitable, or similar relief from a court of competent jurisdiction as necessary to enforce its rights
hereunder without the requirement of arbitration. 
  

 40 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 13.6 Except as specifically provided for herein, the waiver from time to time by either
of the Parties of any of their rights or their failure to exercise any remedy shall not operate or be construed as a continuing waiver of same or of any other of such Party’s rights or remedies provided in this Agreement. 

13.7 In case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby. Any provision of this Agreement held invalid or unenforceable in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.

 13.8 All notices and other communications provided for herein shall be dated and in writing and shall be deemed to have been
duly given (a) on the date of delivery, if delivered personally, by e-mail or by facsimile machine, receipt confirmed, (b) on the following business day, if delivered by a nationally recognized overnight courier service, with receipt
acknowledgement requested, or (c) three business days after mailing, if sent by registered or certified mail, return receipt requested, postage prepaid, in each case, to the Party to whom it is directed at the following address (or at such
other address as any Party hereto shall hereafter specify by notice in writing to the other Parties hereto): 
 If to BDSI: 

Arius Pharmaceuticals, Inc. 
 801 Corporate
Center Drive, Suite 210 
 Raleigh, North Carolina 27607 USA 

Attn: Mark Sirgo, Chief Executive Officer 

Telephone: (919) 582-9050 
 Facsimile:
(919) 582-9051 
  

 41 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 If to Kunwha: Kunwha Pharmaceutical Co., Ltd. 

Kunwha Bldg, 94, Karak-Dong, Songpa-Gu, Seoul, 138-804, Korea 

Attn: Sang-jin Bae, Chief Executive Officer 

Telephone: 82-2-2047-7784 
 Facsimile:
82-2-443-0587 
 It is expressly agreed that BDSI and Kunwha shall be independent contractors and that the relationship between
the two Parties shall not constitute a partnership or agency of any kind. Neither BDSI nor Kunwha shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other
Party, without the prior written consent of the other Party. 
 13.9 The Parties hereto agree that they have been represented by
counsel during the negotiation and execution of this Agreement and, therefore, waive the application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the
Party drafting such agreement or document. Whenever the context hereof shall so require, the singular shall include the plural, the male gender shall include the female gender and neuter, and vice versa. 

13.10 Kunwha and BDSI shall consult with each other before issuing any press release with respect to this Agreement or the transactions
contemplated hereby and neither shall issue any such press release or make any such public statement without the prior consent of the other, which consent shall not be unreasonably withheld; provided, however, (a) that a Party may, without the
prior consent of the other Party, issue such press release or make such public statement as may upon the advice of counsel be required by law or the rules and regulations of the Nasdaq or any other stock exchange, or (b) if it has used
reasonable efforts to consult with the other Party prior thereto, (such consent shall be deemed to have been given if the recipient of the press release or public statement fails to respond to the other Party within 48 hours after the
recipient’s receipt of such press release or public statement). No such consent of the other Party shall be required to release information which has previously been made public. 

 

 42 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 13.11 This Agreement (and any exhibits or appendices hereto) sets forth all of the
covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes and terminates all prior agreements and understandings between the
Parties. There are no covenants, promises, agreements, warranties, representations conditions or understandings, either oral or written, between the Parties other than as set forth herein. No subsequent alteration, amendment, change or addition to
this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. 

13.12 Upon *** prior written notice from either Party (the “Requesting Party”), the Party receiving such notice (the
“Audited Party”) shall permit an independent certified public accountant selected by the Requesting Party and reasonably acceptable to the Audited Party to audit and/or inspect only those books and records (including but not limited to
financial records) as may be necessary pursuant to the terms of the applicable Section of this Agreement granting the applicable inspection rights to the Requesting Party pursuant to this section. Any such independent accounting firm shall be
subject to the confidentiality provisions of this Agreement. A copy of any report provided to a Party by the accountant shall be given concurrently to the other Party. Subject to the terms of this paragraph, such inspection shall be conducted
(a) at the sole cost of the Requesting Party and (b) during the Audited Party’s normal business hours. If the applicable audit involves the calculation of payments to be made by one Party to the other Party and such accounting firm
concludes that such calculations erroneously resulted in an overpayment or underpayment by one Party to the other Party with respect to any payment(s) due hereunder (a “Calculation Error”), within *** of the date of delivery of such
accounting firm’s report concluding that a Calculation Error occurred, the amount overpaid shall be repaid or the amount underpaid shall be augmented as necessary to correct the underpayment or overpayment caused by such Calculation Error, and
if such Calculation Error resulted in an overpayment to or an underpayment from the Party responsible for such error, such Party shall pay interest on such amount at a rate equal to *** or, if less, the maximum legally permissible interest rate,
calculated on the number of days such payments are paid after the date such payments are due. If the Audited Party was responsible for the Calculation Error and such Calculation Error was greater than *** of the proper amount payable with respect to
any particular reporting period or invoiced amount, the Audited Party shall be solely responsible for the reasonable, documented costs associated with the audit. The rights granted to BDSI under this Section 13.12, and any other audit or
inspection rights under this Agreement, may be exercised by CDC IV, LLC or Arius Two, Inc. (or any successor in interest to either of the foregoing) in a manner consistent with similar rights established with respect to each of them in the
agreements between CDC IV, LLC, Arius Two, Inc., and BDSI concerning the Licensed Technology. 
  

 43 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 13.13 The captions contained in this Agreement are not a part of this Agreement, but are
merely guides or labels to assist in locating and reading the several Articles hereof. 
 13.14 This Agreement may be executed
in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Signatures to this Agreement may be transmitted via facsimile and such signatures shall be deemed to be
originals. 
 [Signature page to follow.] 

 

 44 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 IN WITNESS WHEREOF, both BDSI and Kunwha have executed this LICENSE AND SUPPLY
AGREEMENT, in duplicate originals, by their respective officers hereunto duly authorized, the day and year first above written. 
  

									
	ARIUS PHARMACEUTICALS, INC.	 		 	KUNWHA PHARMACEUTICAL CO., LTD.
					
	By:	 	 /s/  Mark A. Sirgo
	 		 	By:	 	 /s/  Bae, Sang-Jin

					
	Name:	 	 Mark A. Sirgo
	 		 	Name:	 	 Bae, Sang-Jin

					
	Title:	 	 President and Chief Executive Officer
	 		 	Title:	 	 President and Chief Executive Officer

 

 45 

 CONFIDENTIAL TREATMENT REQUESTED 

WITH RESPECT TO CERTAIN PORTIONS HEREOF 

DENOTED WITH “***” 
  

 Annex I 

Product and Packing Specifications 

[NOTE: To be inserted.] 
  

 46Non-Employee Directors Deferred Stock Units Program

 Exhibit 10.10 

Summary of Terms of Outside Director Deferred Stock Units 

Type of Award. Each Deferred Stock Unit (a “DSU”) gives a director the right to receive one share of Common Stock at a future date.

 Stock Incentive Plan. The DSUs and related shares of Common Stock are granted under the Company’s 2001 Stock Incentive Plan.

 Amount of Award. $125,000 per year; the closing stock price on the date of grant is divided into $125,000 to determine the number of
DSUs issued to each outside director. 
 Timing of Award. Grants are made annually immediately after the annual meeting. 

Payment of Award. The award will be paid, to the extent vested, upon cessation of board service unless deferred. 

Payment Deferral. A director can elect to defer payment of the award beyond the scheduled payment date, subject to the requirements of
Section 409A. 
 Payment Form. The award will be settled in shares of Common Stock equal to the number of DSUs in a director’s
account at the time of payment. No fractional shares will be issued. Any fractional shares will be rounded down to a whole number of shares. 

Vesting. A DSU award vests over three years, one-third immediately after each of the next three annual meetings after the grant date. 

Accelerated Vesting. Vesting would accelerate on: 
  

	 	•	 	 change of control 

  

	 	•	 	 retirement at normal retirement age, i.e., age 71 

  

	 	•	 	 death 

  

	 	•	 	 disability 

 Dividend
Equivalents. On each date on which the Company pays a dividend on Common Stock, DSUs will receive the benefit of the value of such dividend. Not less often than annually the value of such dividends will be divided by the closing stock price
and the resulting number of additional whole or fractional DSUs will be credited to the directors. 
 Restrictions on Transfer. DSUs are
not transferable before payment date. 
  
  

August 2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]